Albany, NY -- (SBWIRE) -- 02/06/2017 -- Novel drug delivery systems (NDDS) in cancer therapy comprises technologies such as liquid embolics, nanoparticles, and embolization devices that offer unique ways to cure cancer. In recent years, there has been increasing incidence of various types of cancer across the globe. Technological advances have led to the growth of new therapies. There have also been many developments in drug delivery systems due to the increasing government funding. All these factors have led to the growth of the global novel drug delivery systems (NDDS) in cancer therapy market.
PDF Containing Future Market Trends of Novel Drug Delivery Systems (NDDS) in Cancer Therapy is available at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3590
According to the publication, the global NDDS in cancer therapy market is expected to exhibit a whopping 23.70% CAGR from 2014 to 2020. However, strict government regulations and the high cost of new products can hamper the growth of the global market.
The report's authors have segmented the global NDDS in cancer therapy market on the basis of technology and region. Based on technology, the global NDDS in cancer therapy market is classified into embolization particles, liquid embolics, and nanoparticles. In 2013, the nanoparticles drug delivery systems segment stood at US$3,307.7 mn and is projected to exhibit a 24.70% CAGR from 2014 to 2020. Nanoparticles such as Megace ES (megestrol acetate) Abraxane (paclitaxel) DepoCyt (liposomal cytarabine), DaunoXome (daunorubicin citrate), Myocet (doxorubicin), and Doxil (doxorubicin) are approved as novel drug delivery systems in cancer therapy. The liquid embolics segment is predicted to record a steady 4.90% CAGR from 2014 to 2020.
Based on region, the global NDDS in cancer therapy market is divided into Europe, Asia Pacific, North America, and Rest of the World. In 2013, North America accounted for a massive 46.6% of the global NDDS in cancer therapy market. The increasing number of cancer patients, advanced healthcare infrastructure, and favorable reimbursement policies are the factors that can be held responsible for the growth of the North America NDDS in cancer therapy market. In 2013, Europe held a share of 29.2% in the global NDDS in cancer therapy market. Technical advancements in the development of innovative products and the increasing number of pipeline products are projected to benefit the Europe NDDS in cancer therapy market. The Asia Pacific NDDS in cancer therapy market is projected to expand at a 22.60% CAGR from 2014 to 2020, propelled by the development of economies such as India, China, Japan, and Australia.
Read the Present Market Status of Novel Drug Delivery Systems (NDDS) in Cancer Therapy at: http://www.transparencymarketresearch.com/ndds-in-cancer-therapy-market.html
Advanced Medical Isotope Corporation, Eckert & Ziegler BEBIG, Bind Therapeutics, Polysciences, Inc., Nanobiotix, CeloNova BioSciences, Inc., Covidien, plc, EmboMedics, Inc., Cook Medical, Inc., and Mo-Sci Corporation are some of the prominent companies operating in the global NDDS in cancer therapy market.
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.